Ding M, et al. - Through a total of 37 patients with 38 primary papillary thyroid microcarcinoma (PTMC) nodules underwent radiofrequency ablation (RFA) between September 2014 and December 2017, the researchers assessed the security, efficiency, and long-term outcomes of ultrasound-guided RFA for the treatment of PTMC. For the treatment of 37 patients with 38 PTMC nodules, RFA with a low power of 20 W was employed. All nodules attained complete ablation with no complications and alterations in the thyroid function. A decline in the volume of the nodules was observed during follow-up. Thirty-seven out of 38 nodules were completely aborted with no relapse seen in all 37 patients at a median follow-up of 6 months. Hence, for the treatment of PTMC, low-power RFA exhibited excellent safety and promising efficiency outcomes. Moreover, RFA could be an alternative treatment choice for PTMC patients, in addition to surgery and active surveillance.